ClinicalTrials.gg
Not yet recruitingNCT07695415CIPN TBSUpdated Sep 30, 2026

Network-Guided Theta Burst Stimulation for Breast Cancer With Chemotherapy-Induced Peripheral Neuropathy: Clinical and fMRI Biomarker Evidence

An interventional study of pcTBS in CIPN - Chemotherapy-Induced Peripheral Neuropathy and Breast Cancer, sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. Not yet recruiting at 1 site in Taiwan. Open to female participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Not applicable, Interventional, and Treatment

Updated Sep 30, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 380 studies in Breast Neoplasms with a site in Taiwan — 69 open to participants now, 134 under way, 60 of them phase 3. Breast Neoplasms · Taiwan.

Planned enrollment
290th of 332
40 · median 222
Started
2026
with 13 others
No phase
73 of 380
23 open now
Primary completion
2028-12
later than 105 of 133 live
Registered
374th of 380
by date

Among the 380 studies in Breast Neoplasms with a site in Taiwan, this one is the 290th largest by planned enrollment of the 332 interventional ones that give a count, is one of 14 that started in 2026, is one of 73 with no phase, reaches primary completion later than 105 of the 133 other live ones, and was the 374th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

69 of the 380 studies in Breast Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

64 more — sign in →

All 69 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 20 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 380 studies in Breast Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating complication among breast cancer survivors, frequently associated with chronic neuropathic pain that remains inadequately controlled by pharmacological treatments. Emerging evidence suggests that CIPN pain is related to maladaptive reorganization of pain-related brain networks, highlighting the potential of non-pharmacological, brain-based neuromodulation strategies.

Among the variants of theta burst stimulation (TBS), both prolonged constant theta burst stimulation (pcTBS) and intermittent theta burst stimulation (iTBS) have facilitating effects of cortical excitability. The treatment time for pcTBS (1 min and 44 s, 1200 pulses) is much shorter than that of iTBS and traditional repetitive transcranial magnetic stimulation (rTMS); therefore, pcTBS seems to be a promising neuromodulation method for chronic pain and head-to-head comparison between pcTBS and iTBS has never been done before.

The aim of this two-year randomized, cross-over trial project is 1) to compare the effects of pcTBS and iTBS and determine the optimal TBS paradigm for alleviating CIPN pain a sequential focus on distinct cortical targets; 2) to implement a prospectively defined, network-guided framework using fMRI to characterize sensorimotor and pain-related brain connectivity and to examine whether baseline network features and stimulation-induced connectivity changes moderate clinical outcomes.

In Year 1, 20 breast cancer patients with CIPN will be recruited and randomly assigned to two groups: Group I will initially receive pcTBS over M1 for 5 consecutive days and then iTBS over M1 after a 8-week "wash-out" period. Group II will initially receive iTBS over M1 for 5 consecutive days and then pcTBS over M1 after a 8-week "wash-out" period. In year 2, the stimulation target will be changed to dorsolateral prefrontal cortex (DLPFC) to evaluate analgesic effects, and associated brain network changes related to cognitive-affective pain modulation.

MRI-based neuronavigation will be used to ensure precise and reproducible stimulation targeting. Both resting-state and task-based functional MRI will be acquired before stimulation and used prospectively to identify individualized pain-relevant cortical hotspots within predefined anatomical regions (M1 or DLPFC). Resting-state fMRI will be repeated within 24 hours after the final stimulation session to evaluate treatment-related changes in brain networks. Pain intensity measured by the visual analog scale will serve as the primary outcome, with secondary outcomes including Neuropathic Pain Symptom Inventory, Depression Anxiety Stress Scale 21 and pressure pain threshold testing. Primary and secondary outcomes will be evaluated immediately after the last stimulation session and again at 4-week follow-up.

By integrating a clinically efficient trial design with network-informed neuroimaging, this project is expected to provide target-specific evidence for TBS in CIPN pain and to establish a foundation for future precision-guided neuromodulation studies.

03

Conditions studied

  • CIPN - Chemotherapy-Induced Peripheral Neuropathy
  • Breast Cancer

Browse trials for

Keywords

  • CIPN
  • breast cancer
  • theta burst stimulation
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
20 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • breast cancer patients aged between 20- and 80-years-old with CIPN
  • history of receiving chemotherapy including taxane-based neurotoxic agents
  • with neuropathic pain, score≥3 in a 0-10 VAS pain scale.
  • with fair cognition and can cooperate to evaluate pain severity.
  • neither at end-stage cancer nor at the estimated survival time less than 6 months.

Exclusion criteria

Exclusion Criteria:

  • brain tumor or history of epilepsy
  • intracranial metallic devices, artificial cochleae, pacemakers, or any other metal device
  • recent myocardial ischemia or unstable angina
  • severe cognitive dysfunction or pregnancy
  • injuries or fractures in the part of neuropathic pain
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group I

    Group I will initially receive pcTBS over M1 for 5 consecutive days and then iTBS over M1 after a 8-week "wash-out" period

    Other: pcTBS

  • Active comparator
    Group 2

    Group II will initially receive iTBS over M1 for 5 consecutive days and then pcTBS over M1 after a 8-week "wash-out" period

    Other: pcTBS

Interventions

  • OtherpcTBS

    Intermittent TBS (iTBS) applies 2 s of TBS trains repeated every 10 s for a total of 20 cycles (600 pulses, total 190 s) and increases cortical excitability for at least 20 min. pcTBS consisted of three pulses at 50 Hz (i.e., 60 ms) repeated 400 times at intervals of 200 ms (a total of 1,200 pulses in 1 min and 44 s)

06

What researchers measure

Primary outcomes

  1. Visual analogue pain scale (VAS)

    Patients will be instructed to rate their mean daily pain on a 0-100 visual analogue pain scale (VAS).

    Time frame: before the first and after the fifth rTMS session in each treatment period

Secondary outcomes

  1. Neuropathic Pain Symptom Inventory

    NPSI is comprised of five subscales for assessing the diverse symptoms of neuropathic pain, including burning spontaneous pain (burning), pressing spontaneous pain (pressing), paroxysmal pain (paroxysmal), evoked pain (evoked), and paresthesia/dysesthesia.

    Time frame: before and after 5-day treatment section

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 2,666 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 25 months is below that.

Counting every sponsor, half of 2,776 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartEst.
Nov 1, 2026was Aug 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Nov 1, 2026
Sep 30, 2026
Eligibility
5 inclusion criteria added, 1 removed; 5 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • Removeda. breast cancer patients aged between 20- and 80-years-old with CIPN b. history of receiving chemotherapy including taxane-based neurotoxic agents c. with neuropathic pain, score≥3 in a 0-10 VAS pain scale. d. with fair cognition and can cooperate to evaluate pain severity. e. neither at end-stage cancer nor at the estimated survival time less than 6 months.
  • Addedbreast cancer patients aged between 20- and 80-years-old with CIPN
  • Addedhistory of receiving chemotherapy including taxane-based neurotoxic agents
  • Addedwith neuropathic pain, score≥3 in a 0-10 VAS pain scale.
  • Addedwith fair cognition and can cooperate to evaluate pain severity.
  • Addedneither at end-stage cancer nor at the estimated survival time less than 6 months.
Exclusion criteria
  • Removeda. brain tumor or history of epilepsy b. intracranial metallic devices, artificial cochleae, pacemakers, or any other metal device c. recent myocardial ischemia or unstable angina d. severe cognitive dysfunction or pregnancy e. injuries or fractures in the part of neuropathic pain
  • Addedbrain tumor or history of epilepsy
  • Addedintracranial metallic devices, artificial cochleae, pacemakers, or any other metal device
  • Addedrecent myocardial ischemia or unstable angina
  • Addedsevere cognitive dysfunction or pregnancy
  • Addedinjuries or fractures in the part of neuropathic pain
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Aug 1, 2026→Nov 1, 2026
    Eligibility 5 inclusion criteria added, 1 removed; 5 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Removeda. breast cancer patients aged between 20- and 80-years-old with CIPN b. history of receiving chemotherapy including taxane-based neurotoxic agents c. with neuropathic pain, score≥3 in a 0-10 VAS pain scale. d. with fair cognition and can cooperate to evaluate pain severity. e. neither at end-stage cancer nor at the estimated survival time less than 6 months.
    • Addedbreast cancer patients aged between 20- and 80-years-old with CIPN
    • Addedhistory of receiving chemotherapy including taxane-based neurotoxic agents
    • Addedwith neuropathic pain, score≥3 in a 0-10 VAS pain scale.
    • Addedwith fair cognition and can cooperate to evaluate pain severity.
    • Addedneither at end-stage cancer nor at the estimated survival time less than 6 months.
    Exclusion criteria
    • Removeda. brain tumor or history of epilepsy b. intracranial metallic devices, artificial cochleae, pacemakers, or any other metal device c. recent myocardial ischemia or unstable angina d. severe cognitive dysfunction or pregnancy e. injuries or fractures in the part of neuropathic pain
    • Addedbrain tumor or history of epilepsy
    • Addedintracranial metallic devices, artificial cochleae, pacemakers, or any other metal device
    • Addedrecent myocardial ischemia or unstable angina
    • Addedsevere cognitive dysfunction or pregnancy
    • Addedinjuries or fractures in the part of neuropathic pain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07695415
Lead sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Yi-shiung Horng, MD., PhD.
Contact
yshorng2015@gmail.com
886-2-66289779

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion